<DOC>
	<DOC>NCT01919125</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and tolerability of single-dose administration of IDX719 in participants with normal hepatic function and participants with varying degrees of hepatic impairment.</brief_summary>
	<brief_title>Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Read and sign the written informed consent form (ICF) after the nature of the study has been fully explained. All subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug. Male subjects have agreed not to donate sperm from Day 1 through 90 days after the last dose of study drug. Pregnant or breastfeeding. Other clinically significant medical conditions or laboratory abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
</DOC>